vivani.com - Utang jangka cendhak marang modal VANI

The daily price action for Vivani Medical, Inc. (VANI) shown on this chart reflects the 0.14 metric. Business growth is constrained by stringent patent laws and rigorous FDA oversight, which necessitate colossal investments. The organization develops subcutaneous systems for the prolonged administration of obesity and diabetes medications, replacing frequent injections. The project is currently in the clinical trial phase, where high research expenses are hindering the path to profitability.

This ratio determines the proportion of short-term liabilities with maturities exceeding one year within the equity structure, measuring the company's dependence on operational debt financing. For Vivani Medical, Inc. (VANI), which develops long-term implantable drug delivery systems, the short-term debt-to-equity ratio reflects the balance between R&D expenditures and liquidity risk, allowing for an assessment of asset stability during the scaling of module replacement cycles.